300357:SZSEZhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Class A Analysis

The stock is trading at CNY 21.85, which sits below its 20‑day SMA of 22.70 and well under the 50‑day SMA of 24.64, indicating short‑term weakness. Momentum indicators are bearish – the RSI is at 34.8, the MACD line sits below its signal and the histogram is negative, and the price is flirting with the computed support level of 21.18 while facing resistance near 24.55. Volatility is elevated at roughly 26% over the past 30 days, yet the beta of 0.47 suggests the share moves less than the broader market. Valuation metrics reinforce the downside pressure: a trailing P/E of 26.98 exceeds the industry average of 24.71 and the DCF‑derived fair value of just CNY 5.02 implies an upside/downside disparity of over 75%. Fundamentally, the company delivers robust profitability with a gross margin of 95%, operating margin of 38% and a profit margin of 39%, alongside a healthy ROE of 15% and ROA of 9.5%. Revenue is expanding at 10.7% YoY, cash balances are strong at CNY 1.33 bn, debt is minimal, and the dividend yield of 1% is supported by a low payout ratio of 27%, suggesting sustainability. These strengths provide a solid foundation for medium‑term investors despite the current pricing disconnect.